lifestyle.thenyctimes.com

Author: Eton Pharmaceuticals

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

March 19, 2026
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026

March 3, 2026
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

March 2, 2026
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution

February 25, 2026
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th

February 20, 2026
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

February 9, 2026